Chengda Pharmaceutical: The company was commissioned by Pfizer’s API factory to customize the development of pharmaceutical intermediates_ Oriental Fortune Network

Summary

[Chengda Pharmaceutical: The company was entrusted by the Pfizer API factory to customize the development of pharmaceutical intermediates]Chengda Pharmaceutical (301201.SZ) stated on the investor interaction platform on January 27 that the company was entrusted by the Pfizer API factory for the development of pharmaceutical intermediates. Its custom research and development of pharmaceutical intermediates. At present, the revenue of cooperative products accounts for a small proportion of the company’s operating revenue, and it has not had a significant impact on the company’s performance. Investors are advised to pay attention to investment risks and make prudent decisions. (Daily Economic News)

An investor asks a question on the investor interactive platform: Your company and thePfizerDo you have cooperation with other large pharmaceutical companies, and do you provide APIs for them?

　　Chengda Pharmaceutical(301201.SZ) stated on the investor interactive platform on January 27 that the company wasPfizerCommissioned by the API factory to develop custom pharmaceutical intermediates for it.The current revenue of cooperative products accounts for the company’sOperating incomeThe proportion is relatively small, and the company has notperformanceIf it has a significant impact, investors are advised to pay attention to investment risks and make prudent decisions.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 33

Original title: Chengda Pharmaceutical: The company was commissioned by the Pfizer API factory to customize the development of pharmaceutical intermediates for it